Biodesix Inc
NASDAQ:BDSX

Watchlist Manager
Biodesix Inc Logo
Biodesix Inc
NASDAQ:BDSX
Watchlist
Price: 1.48 USD 1.37% Market Closed
Market Cap: 215.3m USD
Have any thoughts about
Biodesix Inc?
Write Note

Net Margin
Biodesix Inc

-66.8%
Current
-123%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-66.8%
=
Net Income
-43.8m
/
Revenue
65.6m

Net Margin Across Competitors

Country US
Market Cap 215.3m USD
Net Margin
-67%
Country US
Market Cap 75.6B EUR
Net Margin
1%
Country US
Market Cap 77.9B USD
Net Margin
1%
Country US
Market Cap 56B USD
Net Margin
1%
Country DE
Market Cap 26B EUR
Net Margin
3%
Country DE
Market Cap 18.9B EUR
Net Margin
-2%
Country US
Market Cap 19.3B USD
Net Margin
3%
Country US
Market Cap 17.7B USD
Net Margin
-2%
Country US
Market Cap 17.1B USD
Net Margin
9%
Country DE
Market Cap 13B EUR
Net Margin
3%
Country US
Market Cap 12.7B USD
Net Margin
7%
No Stocks Found

Biodesix Inc
Glance View

Market Cap
215.3m USD
Industry
Health Care

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

BDSX Intrinsic Value
1.96 USD
Undervaluation 24%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-66.8%
=
Net Income
-43.8m
/
Revenue
65.6m
What is the Net Margin of Biodesix Inc?

Based on Biodesix Inc's most recent financial statements, the company has Net Margin of -66.8%.